m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer
m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer
复制标题
m6A RNA 甲基化调节因子可促进膀胱癌的恶性进展并影响预后
DOI：
10.1042/bsr20192892
复制
发表时间：
2019-12-20
影响因子：
4
通讯作者：
Zhang, Shu-fang
中科院分区：
文献类型：
--
作者：
Chen, Mei;Nie, Zhen-yu;Zhang, Shu-fang
N6-甲基腺苷（m6 A）是信使RNA（mRNA）修饰的最常见形式。越来越多的研究证明，m6 A RNA甲基化调节因子在许多癌症中过表达，并通过m6 A RNA甲基化调节因子的动态调节参与癌症的发展。然而，m6 A RNA甲基化调节剂在膀胱癌（BC）中的预后作用知之甚少。在本研究中，我们从癌症基因组图谱（TCGA）数据库下载mRNA表达数据以及相应的临床和预后信息。通过Kolmogorov-Smirnov检验评估m6 A RNA甲基化调节因子与BC患者临床病理变量之间的关系。m6 A RNA甲基化调节因子的表达与BC患者的不同临床病理变量差异相关。然后应用最小绝对收缩和选择算子（LASSO）考克斯回归模型来鉴定三种m6 A RNA甲基化调节剂。风险特征构造如下：0.164FTO -（0.081YTHDC1+0.032WTAP）。根据风险特征，计算每例患者的风险评分，并将患者分为高风险组和低风险组。高危组总生存率明显低于低危组。风险信号不仅是BC患者的独立预后标志物，也是临床病理变量的预测因子。总之，m6 A RNA甲基化调节因子可以参与BC的恶性进展，并且具有三种选定的m6 A RNA甲基化调节因子的风险特征可能是指导BC患者个性化治疗的有希望的预后生物标志物。
N6-methyladenosine (m6A) is the most common form of messenger RNA (mRNA) modification. An increasing number of studies have proven that m6A RNA methylation regulators are overexpressed in many cancers and participate in the development of cancer through the dynamic regulation of m6A RNA methylation regulators. However, the prognostic role of m6A RNA methylation regulators in bladder cancer (BC) is poorly understood. In the present study, we downloaded the mRNA expression data from The Cancer Genome Atlas (TCGA) database and the corresponding clinical and prognostic information. The relationship between m6A RNA methylation regulators and clinicopathological variables of BC patients was assessed by the Kolmogorov-Smirnov test. The expression of the m6A RNA methylation regulators was differentially associated with different clinicopathological variables of BC patients. The least absolute shrinkage and selection operator (LASSO) Cox regression model was then applied to identify three m6A RNA methylation regulators. The risk signature was constructed as follows: 0.164FTO - (0.081YTHDC1+0.032WTAP). Based on the risk signature, the risk score of each patient was calculated, and the patients were divided into a high-risk group and a low-risk group. The overall survival (OS) rate of the high-risk group was significantly lower than that of the low-risk group. The risk signature was not only an independent prognostic marker for BC patients but also a predictor of clinicopathological variables. In conclusion, m6A RNA methylation regulators can participate in the malignant progression of BC, and a risk signature with three selected m6A RNA methylation regulators may be a promising prognostic biomarker to guide personalized treatment for BC patients.